menu

NEWS

Blood-based microRNA signature may predict survival in immunotherapy-treated NSCLC

 March 31, 2022 A blood-based signature of five microRNAs demonstrated the ability to predict OS of patients with lung cancer receiving immunotherapy and stratify them for treatment, according to a study published in npjPrecision Oncology.  Researchers reported that because the signature appears to work from a single timepoint before treatment, it differs from classical circulating tumor DNA-based assays, where blood at baseline is typically dynamically compared with follow-up samples. “Importantly, the signature does not require any prior tumor tissue analysis and could be used in an ‘off-the-shelf’ manner,” Bruno R. Steinkraus, PhD, chief scientific officer at Hummingbird Diagnostics, told Healio. “We believe our test could...

READ MORE
Hummingbird Diagnostics Announces Publication of Study on the Utility of miRisk, a Blood-based microRNA Analysis, to Predict Overall Survival for Advanced Non-Small Cell Lung Cancer in npj Precision Oncology

—Results describe development of analysis to uncover association of several microRNAs with overall survival following initiation of immunotherapy— —Blood-based test holds potential for broad applicability for the management of patients with cancer—March 31, 2022 05:00 AM Eastern Daylight Time  March 31, 2022 05:00 AM Eastern Daylight Time  HEIDELBERG, Germany–(BUSINESS WIRE)–Hummingbird Diagnostics GmbH, a leader in reading blood-based microRNAs for early disease detection and characterization, today announced the publication of a study in the journal npj Precision Oncology that describes the discovery and validation of miRisk, a first-of-its-kind microRNA (miRNA) biomarker signature that offers the prospect of a blood-based companion diagnostic...

READ MORE
Streck establishes partnership with Ceres Nanosciences to distribute COVID-19 wastewater surveillance solution

La Vista, NE – January 10, 2022 Streck today announced a partnership with Ceres Nanosciences to distribute Nanotrap® Magnetic Virus Particles that provide rapid viral concentration directly from raw sewage. This product dramatically reduces the time and effort required to test wastewater samples for COVID-19 surveillance. Wastewater surveillance can act as an early-warning system for COVID-19 “hotspots” within a community. The Ceres Nanotrap Magnetic Virus Particles facilitate a streamlined workflow, improved sensitivity, and reduced time to results. Nanotrap Magnetic Virus Particles are For Research Use Only. Not for use in diagnostic procedures. Traditional methods for concentration of virus from wastewater are...

READ MORE
Ceres Nanosciences Establishes Nine Wastewater-based COVID-19 Surveillance Centers of Excellence Under NIH RADx Initiative

MANASSAS, Virginia – November 9, 2021 Ceres Nanosciences (Ceres), a privately held company that makes innovative products to improve life science research and diagnostic testing, is announcing the establishment of nine new wastewater-based epidemiology centers of excellence, as part of the April 2021 $8.2 million award from the National Institutes of Health (NIH) Rapid Acceleration of Diagnostics (RADxSM) initiative. Wastewater-based epidemiology can help communities monitor infection dynamics for SARS-CoV-2 and can serve as an early-warning system for the virus in a population, but widespread implementation has been stymied by lack of robust, high-throughput viral concentration methods.​ Ceres’ Nanotrap® Magnetic Virus Particles address...

READ MORE
Genetika+ CEO Talia Cohen Solal Brings Precision Medicine to Brain Health

BioSpace // Published October 21, 2021 | By Gail Dutton Genetika+ CEO and Co-founder Talia Cohen Solal/Courtesy Genetika+.  Depression, historically, has been treated by trial and error until a therapy with a positive and stable outcome can be identified. Genetika+ is changing that with precision, personalized testing that enables the right antidepressant to be selected for patients the first time. “We’re developing a blood test to match therapies to patients,” Talia Cohen Solal, Ph.D., CEO and co-founder of Genetika+, told BioSpace. The test doesn’t directly assay the blood, though. Instead, “We take the blood cells and use stem cell technology to cause...

READ MORE
Genetika+ – A Pioneer in Personalized Medicine for Psychiatry – Raises $10 Million in an Oversubscribed Series A

JERUSALEM AND BOSTON (PRWEB) SEPTEMBER 30, 2021 New investment underscores the company’s promise to transform precision medicine and mental health Genetika+, bringing the first personalized medicine platform for optimizing psychiatric and neurologic patient treatment, announced today that it has closed a $10 million Series A funding round led by GreyBird Ventures, a Boston-based VC focused on precision medicine. Also participating in the round are Meron Capital, Jumpspeed Ventures, Sapir Venture Partners, Howard Morgan Chairman of B Capital Group and Michael Zeisser of FMZ Ventures and former Chairman, Investments at Alibaba Group. Genetika+’s lead solution personalizes antidepressant treatment for each patient. The...

READ MORE
1 2 3 4 5 6 9
GreyBird Ventures

is named after the arctic tern, a bird that migrates 71,000 km annually. As they can live for 30 years, this is the lifetime equivalent of three trips to the moon and back. Not bad for a 100 gram bird. We strive to emulate its size to performance ratio as well as its global reach.

MEET THE PEOPLE

For additional information, please contact: greybird@greybirdventures.com

DISCLAIMER